Piracetam has been studied since the early 1970s and has one of the stranger research profiles in pharmacology. It has been tested in stroke, dementia, dyslexia, cortical myoclonus, vertigo, and sickle cell anemia. It does not sedate. It does not [Read more…]
Modafinil has stronger regulatory backing and clearer evidence for improving wakefulness, while piracetam has a larger body of clinical research in cognitive impairment, a cleaner drug interaction profile, and a long record of tolerability, but no FDA approval in the [Read more…]
For narcolepsy, both modafinil and dextroamphetamine are approved to improve wakefulness. For ADHD, dextroamphetamine is approved, while modafinil is not approved for routine treatment in adults. The key differences involve stimulant intensity, abuse risk classification, and safety considerations, especially cardiovascular [Read more…]
Getting a modafinil prescription requires meeting specific medical criteria tied to diagnosed sleep disorders. In clinical practice, doctors prescribe modafinil for narcolepsy, shift work sleep disorder, or obstructive sleep apnea, not for general fatigue, focus, or energy concerns. Patient accounts [Read more…]
Modafinil is effective at reducing excessive sleepiness in people with diagnosed shift-work sleep disorder. It is FDA-approved for this use and improves alertness, work-related functioning, and mental quality of life during night shifts without disrupting intended sleep. The key limitation [Read more…]
Recent Comments